LPL Financial’s ImmunityBio IBRX Stock Holding History

LPL Financial’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$175K	Buy	+20,000	New	+$151K	﹤0.01%	5802

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

LPL Financial's IBRX Position: Q2 2026 in Review

LPL Financial increased its ImmunityBio (IBRX) stake by 18% in Q2 2026, buying an estimated $1.18M and bringing the position to 1,021,057 shares worth $8.94M. The position accounts for ﹤0.01% of the portfolio, ranked #2254.

LPL Financial first reported a position in IBRX in Q1 2021 and has held it in 13 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

LPL Financial held 1,021,057 shares of ImmunityBio worth $8.94M as of Q2 2026.
LPL Financial bought 156,427 ImmunityBio shares in Q2 2026, an estimated $1.18M.
ImmunityBio made up ﹤0.01% of LPL Financial's portfolio in Q2 2026, its #2254 holding.
LPL Financial first reported a position in ImmunityBio in Q1 2021 and has held it in 13 quarters since.
405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on LPL Financial's 13F filing for Q2 2026, filed 7 Aug 2026.